Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer.
Oncol Res Treat
; 45(11): 681-692, 2022.
Article
in English
| MEDLINE | ID: covidwho-2162084
ABSTRACT
BACKGROUND:
Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results.SUMMARY:
We comprehensively described the clinical benefits of MCT in combination with other treatments in different molecular subtypes of breast cancer and assessed the feasibility of its adoption in varying phases of treatment. Due to the promising preclinical and clinical investigations, it is expected that MCT in combination with other treatments will enhance the advantages of this strategy and apply it to clinical practice. KEY MESSAGE MCT, in combination with other therapeutic interventions, will fully exploit the benefits of this strategy, ushering in a new paradigm in oncology treatment and driving the transformation of cancer into a more manageable chronic disease using newly developed treatment approaches.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Oncol Res Treat
Year:
2022
Document Type:
Article
Affiliation country:
000526481
Similar
MEDLINE
...
LILACS
LIS